- Home
- MGNX vs FGMC Comparison
MGNX vs FGMC Comparison
Compare MGNX & FGMC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGNX
- FGMC
- Stock Information
- Founded
- MGNX 2000
- FGMC 2023
- Country
- MGNX United States
- FGMC United States
- Employees
- MGNX N/A
- FGMC N/A
- Industry
- MGNX Biotechnology: Pharmaceutical Preparations
- FGMC
- Sector
- MGNX Health Care
- FGMC
- Exchange
- MGNX Nasdaq
- FGMC NYSE
- Market Cap
- MGNX 87.7M
- FGMC 100.6M
- IPO Year
- MGNX 2013
- FGMC 2025
- Fundamental
- Price
- MGNX $1.33
- FGMC $9.87
- Analyst Decision
- MGNX Hold
- FGMC
- Analyst Count
- MGNX 9
- FGMC 0
- Target Price
- MGNX $5.33
- FGMC N/A
- AVG Volume (30 Days)
- MGNX 2.0M
- FGMC 28.7K
- Earning Date
- MGNX 08-05-2025
- FGMC 01-01-0001
- Dividend Yield
- MGNX N/A
- FGMC N/A
- EPS Growth
- MGNX N/A
- FGMC N/A
- EPS
- MGNX N/A
- FGMC 0.08
- Revenue
- MGNX $154,050,000.00
- FGMC N/A
- Revenue This Year
- MGNX N/A
- FGMC N/A
- Revenue Next Year
- MGNX N/A
- FGMC N/A
- P/E Ratio
- MGNX N/A
- FGMC $572.91
- Revenue Growth
- MGNX 255.31
- FGMC N/A
- 52 Week Low
- MGNX $0.99
- FGMC $9.53
- 52 Week High
- MGNX $5.77
- FGMC $9.88
- Technical
- Relative Strength Index (RSI)
- MGNX 41.45
- FGMC N/A
- Support Level
- MGNX $1.33
- FGMC N/A
- Resistance Level
- MGNX $2.17
- FGMC N/A
- Average True Range (ATR)
- MGNX 0.17
- FGMC 0.00
- MACD
- MGNX -0.02
- FGMC 0.00
- Stochastic Oscillator
- MGNX 2.38
- FGMC 0.00
About MGNX MacroGenics Inc.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.
About FGMC FG MERGER II CORP
FG Merger II Corp is a blank check company, incorporated for the purpose of merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization or other similar business combination with one or more businesses or entities (Business Combination).